On June 10, 2019, Avalon GloboCare Corp. (AVCO), a leading global developer of cell-based technologies and therapeutics, announced it has achieved a major milestone in bio-production standardization of clinical-grade stem-cell-derived exosomes. The standardized procedure was a direct result of the previously announced co-development program (https://ir.avalon-globocare.com/press-releases/detail/28/avalon-globocare-teams-up-with-weill-cornell-medicine-to) at Weill Cornell Medicine with Yen-Michael Hsu, MD, PhD, as principal investigator. The process has been co-developed and operated within Weill Cornell's cGMP-certified cell therapy facility jointly accredited under the Foundation of Accreditation for Cellular Therapy (FACT), American Association of Blood Banking (AABB), College of American Pathologists (CAP), as well as Clinical Laboratory Improvement Amendment (CLIA). Avalon will hold a press conference to announce the launch of its exosome product commercialization plan, including a series of over-the-counter skincare and wound-healing products with Avalon's Clinical-Grade Tissue-Specific EXosomes as additives (ACTEX), on June 15, 2019 during the 2nd International Aesthetic Industry Conference in Chengdu, China -- the largest conference of its kind in Asia. In addition to product commercialization, this standardization of clinical-grade stem-cell-derived exosomes will lead to parallel development of Avalon's clinical programs, including AVA-202 and AVA-203, for angiogenic/orthopedic regeneration, as well as treatment of fibrotic diseases. "We are pleased to complete such a significant developmental milestone of our exosome program," stated David Jin, MD, PhD, CEO and President of Avalon GloboCare and Co-CEO of its subsidiary GenExosome Technologies.Login Or Register To Read Full Story